MRS MEASUREMENT: TREATMENT RESPONSE TO ANTICONVULSANTS IN JUVENILE BIPOLAR DIS

1.使用双丙戊酸钠进行临床试验，包括 儿童双盲停药后的开放阶段和 患有BD的青少年。假设：双丙戊酸钠将显示出安全性 临床综合评价表对症状反应的疗效 印象量表(CGI)和8岁以后的Young/Fristad躁狂量表 对一组确诊为儿童和青少年的儿童和青少年进行数周的单一治疗 患有躁郁症。2.确定治疗的潜在预测因素 回应。假设：将会有显著的相关性 磁学测量大脑GA13A浓度的变化之间 共振波谱(IHMRS)和治疗反应的变化 治疗两周后用CGI测定双丙戊酸钠。 我们假设大脑中较高的GABA浓度 与异丙丙胺的症状反应降低显著相关 钠盐。

1. Perform a clinical trial with divalproex sodium, consisting of an open phase followed by double blind discontinuation in children and adolescents with BD. hypothesis: Divalproex sodium will show safety and efficacy in symptom response as measured by the Clinical Global Impressions Scale (CGI) and the Young/Fristad Mania Scale after 8 weeks of monotherapy in a group of children and adolescents diagnosed with bipolar illness. 2. Identify potential predictors of treatment response. hypothesis: There will be a significant correlation between change in cerebral GA13A concentration as measured by Magnetic Resonance Spectroscopy (IHMRS), and change in treatment response to divalproex sodium as measured by the CGI after two weeks of therapy. We hypothesize that a higher cerebral GABA concentration will be significantly related to a decrease in symptom response to divalproex sodium.